The effect of different combination therapies on oxidative stress markers in HIV infected patients in cameroon by Ngondi, Judith L et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
AIDS Research and Therapy
Open Access Research
The effect of different combination therapies on oxidative stress 
markers in HIV infected patients in cameroon
Judith L Ngondi*1, Julius Oben1, David Musoro Forkah1, 
Lucein Honore Etame1 and Dora Mbanya2
Address: 1Nutrition, HIV and Health Research Unit, Department of Biochemistry, University of Yaounde I, Cameroon and 2Faculty of Medicine 
and Biomedical Sciences, University of Yaounde I, Cameroon
Email: Judith L Ngondi* - jlngondi@yahoo.com; Julius Oben - juluisoben@hotmail.com; David Musoro Forkah - letame@yahoo.fr; 
Lucein Honore Etame - dfmusoro@yahoo.com; Dora Mbanya - dmbanya@hotmail.com
* Corresponding author    
Abstract
The study assessed the effect of some highly active antiretroviral therapies (HAART), used in the
management of HIV/AIDS in Cameroon, on oxidative stress markers such as malondialdehyde (as
TBARs), albumin, protein carbonyl content and protein sulfhydryls groups. 85 HIV positive patients
(34.8 ± 9.3 years) were on three different highly active antiretroviral therapies (HAART patients).
65 HIV positive patients (32.2 ± 10.9 years) on no treatment (Pre-HAART patients), and 90 non-
HIV infected patients (32.6 ± 9.3 years), were the control groups. Plasma TBARs as well as carbonyl
levels were significantly higher in HIV patients on HAART compared to pre-HAART patients or
non-HIV infected controls. On the other hand, the protein sulfhydryl group content was not
different for patients on HAART compared to pre-HAART patients, but both were significantly
lower than non-HIV infected controls (P < 0.0001, 0.001). The combination treatment Therapy I
[stavudin (80 mg) + Lamivudin (600 mg) + Nevirapin + (400 mg) zidovudin (600 mg)] brought about
a significant (p < 0.05) reduction in the plasma concentration of protein sulfhydrl groups as well as
TBARs compared to Therapy II [stavudin (80 mg) + Lamivudin (300 mg) + nevirapin (400 mg)] or
with combination Therapy III of [zidovudine (600 mg) + lamivudin(300 mg) with efavirenz (600 mg)]
(P < 0.05). The content of the antioxidant, Vitamin C was lower in the plasma of patients on
Therapy I compared to those on Therapy II (P < 0.01) and Therapy III (P < 0.001).
HIV infection therefore increases the oxidative stress process, while antiretroviral combination
therapy increased protein oxidation as well as the level of oxidative stress already present in HIV
infection.
Introduction
The use of antiretroviral therapies (ART) is recommended
worldwide for the management of HIV/AIDS. Different
types of ART or combination therapies are available, and
the prescription and use of a particular therapy depends
on tolerabity, the cost, and the therapeutic objectives. The
initiation of therapy is dependent on diagnosis as well as
serological parameters, with therapy generally started
when the CD4 count is less than 200 lymphocytes/mm3.
WHO currently recommends first-line therapy with two
nucleoside reverse transcriptase inhibitors (NRTIs) and
one non-nucleoside reverse transcriptase inhibitors
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(NNRTI) [1]. Because of the low income of hour popula-
tion, the Cameroon Ministry of public Health is continu-
ously looking for generic drugs which are generally
cheaper. A combination of nevirapin, stavudin, and Lam-
ivudin or lamivudin with zidovudin is frequently pre-
scribed. Different information and refresher seminars are
organised to educate medical practitioners and health
workers on the use and prescription of these therapies,
which still varies from one health facility to another.
Some of the treatment options used may result in bio-
chemical and physiological changes e.g. oxidative damage
resulting from the presence of free radicals or the absence
of antioxidants.
Free radicals are compounds possessing an unpaired elec-
tron, which renders them highly reactive and capable of
causing oxidative damage to all the major macro-mole-
cules in cells, including lipids, proteins and nucleic acids.
A major family of free radicals is the reactive oxygen spe-
cies, derived metabolically from molecular oxygen via
super oxide anions. Oxidative attack on proteins results in
the formation of protein carbonyls [2], often with the loss
of functionality of the parent protein. Polyunsaturated
fatty acids, which are major components of cell mem-
branes, can also undergo free radical attack, producing
lipid peroxidation products like malondialdehyde (MDA)
and 4-hydroxynonenal. Under normal circumstances, the
body is protected from such damage by a careful balance
between pro-oxidants and antioxidants. In extra vascular
spaces, the sulphydryls group of plasma proteins, includ-
ing plasma albumin serve as antioxidants [3], with
enzymes and scavenging chemicals such as Vitamin C and
vitamin E also having antioxidant activities. Certain foods
are good sources of antioxidants, hence the importance of
their inclusion in the treatment of illnesses accompanied
by oxidative stress. Although there are several known side
effects of HIV/AIDS medications, like lipodystrophy, an
increase in the risk of cardiovascular disease, including
heart attacks and stroke etc., there is not sufficient evi-
dence to substantiate the role of free radicals in mediated
oxidative injury in HIV/AIDS infection. This study evalu-
ated the oxidant and antioxidant status of HIV positive
patients in Cameroon.
Methods
Patients
Patients were eligible if they had confirmed HIV infection,
were older than 18 years, and had not taken antiretroviral
drugs before (pre-HAART patients) or being on triple
drugs therapy for least 3 to 6 months. HIV positive out
patients (150) were recruited from the Yaounde Hospital.
Patients were classified according to their sex, immune
status such as the CD4 + count (lymphocytes/mm3) and
viral load measurements. 65 positive patients were not on
any form of antiviral therapy, while 85 were on one of the
different therapies outlined below. These individuals
showed no serological evidence for HBV and or HCV-
infection. The control group comprised of 90 randomly
selected age-matched healthy subjects who showed no
serological evidence for HIV and/or HCV-infection and
no abnormal laboratory finding (blood count, ASAT,
ALAT levels were all within the normal range).
All subjects gave their informed consent before participat-
ing in the study, and the local ethics committee approved
the project.
Different Highly active anti retroviral Therapies (HAART) 
used
Patients on antiviral therapy followed one of the follow-
ing daily therapies:
Therapy I (n = 40): Generic fixed-dose combination of sta-
vudin + lamivudin + nevirapin associated with a generic
fixed-dose combination of zidovudin +Lamivudin;
Therapy II (n = 20): Generic fixed-dose combination of
stavudin+ lamivudin + nevirapin
Therapy III (25): Generic fixed dose combination of zido-
vudin + lamivudin associated with efavirenz.
Sample collection and treatment
Over night (12 hour) fasting venous blood (10 ml) was
collected from all subjects and divided between a
heparinized tube and a tube containing Ethylene Diamine
Tetra Acetate (EDTA). After centrifugation at 3000 g for 10
minutes at 4°C, a sample of the heparinized plasma was
set aside for the analysis of protein sulphydryls and pro-
tein carbonyls. Samples of plasma containing EDTA were
also set aside for the measurement of Vitamin C and
MDA. All samples were stored at -80 °C and analysed
within 2 weeks.
Biochemical analyses in plasma
Total protein was determined using a commercially avail-
able Biuret method [4]. Lipid peroxidation was measured
by the thiobarbituric acid method described in [5], and
results expressed as μmol/l. Protein carbonyl, albumin
and protein sulphydryls concentrations were measured
spectrophotometrically were determined using the meth-
ods of [6-8], Plasma Vitamin C concentration was deter-
mined by the method of Roe and Kuether [9].
Statistical analysis
Values are expressed as mean ± Standard error of mean
(SEM). Data was analysed using the SPSS package, and
normality of distribution of the data assessed using the
normal plot method. The variables were normally distrib-
uted and comparisons made using ANOVA test. Differ-AIDS Research and Therapy 2006, 3:19 http://www.aidsrestherapy.com/content/3/1/19
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ences between groups were assessed using the Bonferonni
procedure.Multiple linear regression analysis was used to
assess the influence of influence of BMI, age, sex, CD4
count and Viral load on oxidative stress markers in
HAART patients. A p value of = 0.05 was considered signif-
icant
Results
Immunological characteristics
The CD4 count was significantly (p < 0.001) lower in the
HIV positive subjects on HAART compared to pre-HAART
patients (Table 1). The viral loads were also found to be
significantly higher for patients on HAART.
Plasma analysis
Measures of lipids and protein oxidation showed a signif-
icantly elevated levels of TBARs (P < 0.0001, 0.0001) and
lower levels of carbonyl (P < 0.0001, 0.0001) in HIV
patients on antiviral therapy compared to those not fol-
lowing therapy or non HIV infected controls (Table 2).
On the other hand, plasma protein sulfhydryls group
(Table 3) was not different for patients on HAART com-
pared to pre-HAART patients, but both were significantly
lower than non HIV infected controls (P < 0.0001, 0.001).
Plasma albumin levels were lower in HIV positive
patients, no difference were found in the level of vitamin
C (Table 3). Patients on Therapies I, II and III had lower
concentrations of carbonyls (p < 0.001) and elevated con-
centrations of TBARs (p < 0.001) compare to pre-HAART
patients (Table 4). Plasma concentrations of sulfhydryls
group of patients on therapy II (p = 0.01) was lower com-
pare to pre-HAART patients but their albumin level (p <
0.01) was higher compare to pre-HAART patients. Vita-
min C concentrations were not different between Pre-
HAART, Therapy II&III patients but patients on Therapy I
had reduced levels of Vitamin C compare to pre-HAART
(p < 0.01), therapy II &III patients (p < 0.001) (Table 5).
Effect of nutritional status and CD4 count on oxidative 
damage seen in subjects on HAART
Our results showed a non significant difference in the oxi-
dative stress markers levels between patients with and
without CD4 count less than 200 lymphocytes/mm3
(Table 7).
The effect of nutritional status was assessed using weight
status criteria and plasma albumin level. Weight status
was classified using body mass index, into the following
categories: lean (<20 kg/m2), normal (20–24.9 kg/m2),
overweight or obesity (>25 kg/m2). Among pre-HAART
patients 33.9% had normal weight and 66.1% were over-
weight and only albumin level was significantly different
between the two categories (Table 8). In HAART group,
11.8%, 49.4%, 38.8% patients were lean, normal or over-
weight respectively. In this group, protein oxidation was
high in lean patients compare to normal or overweight
patients. We noticed a significant decrease in antioxidant
capacity (sulfhydryls group) in both lean and overweight
patients.
A biochemical assessment of nutritional status using
plasma albumin level cut off point of <3.5 g/dl (507
μmol/l) as indicator of malnutrition showed that 53.9%
of pre-HAART and 74.1% of HAART patients had lower
albumin level (Table 9). Lipid oxidation (TBARs) was
increased in pre-HAART patients with normal albumin
level and in HAART patients with lower albumin level.
Protein oxidation process was not affected by albumin
status (Table 8).
Multiple linear regression analysis confirmed that BMI
sex, age and CD4 count and viral load did not had a sig-
nificant impact on TBARs and carbonyls concentrations
but CD4 and Viral load significantly influenced the anti-
oxidant capacity (albumin and (sulfhydryls group) in
HAART patients (Table 9).
Discussion
The present study was designed to investigate the effect of
antiretroviral therapies on oxidative stress markers in HIV
infected patients in Cameroon. Voluntary screening for
HIV infection is not common in Cameroon, and people
will generally be diagnosed when they consult for ill-
nesses and symptoms related to HIV infection. When
patients are diagnosed as HIV positive, therapy is initiated
when the CD4 count is less than 200 lymphocytes/mm3.
The consequence of this is patients being on antiviral ther-
apy when the HIV infection is fairly advanced. When ther-
apy is however initiated, it varies depending on the
Table 1: Characteristics of HIV positive patients on antiviral therapy, without therapy and controls
HIV- pre-HAART HAART
n 90 65 85
Sex (M/F) 20/70 27/38 30/55
Age (years) 34 ± 9.15 33.71 ± 8.56 36.8 ± 8.91
BMI (kg/m2) 25.31 ± 2.44 25.01 ± 3.66 25.19 ± 4.70
CD4 (lymphocytes/mm3) / 496 ± 163 266 ± 137a
Viral load / 26754 ± 8347 111136,33 ± 25281a
Significant differences (aP < 0.0001) are by comparison with the HIV positive patients without therapy (pre-HAART)AIDS Research and Therapy 2006, 3:19 http://www.aidsrestherapy.com/content/3/1/19
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therapeutic objectives, the cost, and their availability on
the market. Our results showed that, HIV infection
increases the oxidative stress process, which is further
increased by the use of ART. This was observed by the sig-
nificantly higher TBARs (lipid peroxidation) concentra-
tions (Table 4), suggesting an increase in lipid
peroxidation [10]. Among the three therapeutic regimes
used patients on Therapy I which is the association of a
commonly used fixed-dose combination therapy [11]as
monotherapy, thereby combining it with a generic fixed-
dose combination of Lamivudin and zidovudin, showed
lower plasma concentration of the antioxidant Vitamin C
Table 3: The effect of HIV infection and the antiretroviral therapy, on plasma levels of antioxidants.
HIV negative (n = 90) HIV+
Groups pre-HAART (n = 65) HAART (n = 85)
Sulfhydryls (nmol/mg protein) 8.03 ± 0.68 4.90 ± 2.78a 3.87 ± 2.85a
Albumin (mol/l) 0.94 ± 0.32 0.41 ± 0.05a 0.49 ± 0.28ab
Vitamin C (μmol/l) 27.1 ± 4.22 26 ± 4.01 21.43 ± 4.53
Significant differences (aP < 0.0001) are by comparison with the control group (HIV Negative), (bP < 0.0001) are by comparison with the HIV 
positive patients without therapy (pre-HAART)
Table 2: The effect of HIV infection and the antiretroviral therapy, on markers of oxidative stress (carbonyls and TBARs).
Groups HIV negative (n = 90) HIV positve
pre-HAART (n = 65) HAART (n = 85)
Carbonyls (nmol/mg protein) 1.07 ± 0.27 1.34 ± 0.98a 0.84 ± 0.90a
TBARS (μmol/l) 1.3 ± 0.12 4.2 ± 0.77a 6.28 ± 1.3ab
Significant differences (a P < 0.0001) are by comparison with the control group (HIV Negative), (b P < 0.0001) by comparison with the HIV positive 
patients without therapy (pre-HAART)
Table 4: The effect of HIV infection and different types of antiretroviral therapy, on markers of oxidative stress (carbonyls and 
TBARs).
HIV- HIV+
Groups Control (n = 90) pre-HAART (n = 
65)
Therapy I (n = 40) Therapy II (n = 20) Therapy III (n = 25)
Carbonyls (nmol/
mg)
1.07 ± 0.27 1.34 ± 0.98a 0.79 ± 0.10ab 0.93 ± 0.16b 0.81 ± 0.09ab
TBARS (μmol/l) 1.30 ± 0.12 4.20 ± 0.70a 7.02 ± 2.58ab 5.92 ± 1.46ab 5.84 ± 0.89ab
Significant differences (a P < 0.01) are by comparison with the control group (HIV Negative), (b P < 0.001) are by comparison with the HIV positive 
patients without therapy (pre-HAART)
Table 5: The effect different types of antiretroviral therapy, on plasma levels of antioxidants.
HIV- HIV+
Groups Control (n = 90) pre-HAART (n = 65) Therapy I (n = 40) Therapy II (n = 20) Therapy III (n = 25)
Sulfhydryls (nmol/mg 
protein)
8.03 ±± 0.68 4.90 ± 2.78a 4.5 ± 2.1a 2.70 ± 1.45abc 4.37 ± 2.01a
Albumin (mol/l) 0.94 ± 0.32 0.41 ± 0.05a 0.47 ± 0.24a 0.54 ± 0.31ab 0.47 ± 0.29a
Vitamin C (μmol/l) 27.1 ± 4.22 26 ± 4.01 12.9 ± 2.12ab 22.9 ± 5.01c 28.5 ± 7.45c
Significant differences (aP < 0.001) are by comparison with the control group (HIV Negative), (bP < 0.01) are by comparison with the HIV positive 
patients without therapy (pre-HAART) and (cP < 0.001) by comparison with the HIV positive patients on therapy IAIDS Research and Therapy 2006, 3:19 http://www.aidsrestherapy.com/content/3/1/19
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Table 8: Comparison of oxidative stress markers levels between HIV infected patients with and without hypoalbuminemia
pre-HAART (n = 65) HAART (n = 85)
Albumin sub class (mol/l) <0.507 ≥ 0.507 <0.507 ≥ 0.507
n 35 (53.9%) 30 (25.9%) 63 (74.9%) 22 (25.9%)
BMI (kg/m2) 23.87 ± 0.65 27.83 ± 1.15** 25.11 ± 0.96 25.54 ± 1.47
Albumin (mol/l) 0.35 ± 0.094 0.57 ± 0.05*** 0.33 ± 0.017 0.55 ± 0.018***
CD4 (lymphocytes/mm3) 345.71 ± 59.58 582.25 ± 102.49** 258 ± 42.04 269.38 ± 45.38
Sulfhydryls (nmol/mg protein) 4.73 ± 1.49 5.07 ± 2.7 3.52 ± 1.59 4.24 ± 2.71
TBARS (μmol/l) 3.95 ± 0.56 4.72 ± 0.64** 6.79 ± 1.21 6.11 ± 1.75*
Carbonyls (nmol/mg protein) 0.95 ± 0.17 0.81 ± 0.16 0.82 ± 0.16 0.85 ± 0.18
Significant differences (*P < 0.05; **P < 0.001; ***P < 0.0001) are by comparison with albumin Sub class <0.507 mol/l
Table 6: Comparison of oxidative stress markers levels between HIV infected patients with and without the CD4<200 lymphocytes/
mm3
pre-HAART (n = 65) HAART (n = 85)
CD4 sub class <200 ≥ 200 <200 ≥ 200
n 28 (43,18%) 37 (56.82%) 44 (51.7%) 41(48.3%)
BMI (kg/m2) 23.91 ± 0.64 26.92 ± 1.09* 26.29 ± 1.39 25.22 ± 0.98
Albumin (mol/l) 0.39 ± 0.08 0.57 ± 0.13 0.50 ± 0.10 0.47 ± 0.15
CD4 (lymphocytes/mm3) 93.37 ± 13.01 434.21 ± 71.56** 73.26 ± 15.18 341.83 ± 30.44**
Sulfhydryls (nmol/mg protein) 4. 85 ± 1.30 4.94 ± 2.5 4.30 ± 2.7 3.59 ± 1.20
TBARS (μmol/l) 4.31 ± 0.47 4.82 ± 0.7 6.80 ± 1.62 5.82 ± 1.17
Carbonyls (nmol/mg protein) 1.45 ± 0.10 1.17 ± 0.16 0.83 ± 0.20 0.86 ± 0.14
Significant differences (**P < 0.005; **P < 0.0001) are by comparison with CD4 Sub class <200 lymphocytes/mm3
Table 7: The effect of weight status on Oxidative stress markers levels of HIV infected patients
pre-HAART (n = 65) HAART (n = 85)
BMI Sub class (kg/m2) 20–25 ≥ 25 <20 20–25 ≥ 25
n 22 (33.9%) 43 (66.1%) 10 (11.8%) 42 (49.4%) 33 (38.8%)
BMI (kg/m2) 22.88 ± 0.48 27.63 ± 0.64 18.61 ± 0.32 23.04 ± 0.37 30.01 ± 0.94
Albumin (mol/l) 0.35 ± 0.03 0.51 ± 0.026c 0.57 ± 0.03 0.47 ± 0.027 0.40 ± 0.045
Sulfhydryls (nmol/mg protein) 5.02 ± 1.48 4.80 ± 2.12 3.60 ± 2.1 5.12 ± 2.5 3.39 ± 0.95b
TBARS (μmol/l) 4.09 ± 0.57 4.50 ± 0.77 5.57 ± 1.29 6.76 ± 1.50 6.40 ± 1.43
Carbonyls (nmol/mg protein) 0.93 ± 0.14 0.90 ± 0.2 1.09 ± 0.24 0.82 ± 0.15a 0.78 ± 0.11a
Significant differences (aP < 0.01) are by comparison with BMI Sub class <20 kg/m2
Significant differences (bP < 0.01;cP < 0.004) are by comparison with BMI Sub class 20–25 kg/m2
Table 9: Multiple linear regression analysis showing the influence of BMI, age, sex, CD4 count and Viral load on oxidative stress 
markers in HAART patients
Parameters Independent contributing factors
BMI Age Gender CD4 Viral Load
Carbonyls (nmol/mg protein 0.093 0.140 0.026 -0.139 0.176
Sulfhydryls (nmol/mg protein) 0.104 -0.030 0.015 0.420** -0.407**
TBARS (μmol/l) 0.170 0.060 0.185 -0.190 0.102
Vitamin C (μmol/l) -0.067 -0.010 0.010 -0.091 -0.084
Albumin (mol/l) 0.345* -0.011 0.030 0.320* -0.366*
* p < 0.05, **p < 0.01.AIDS Research and Therapy 2006, 3:19 http://www.aidsrestherapy.com/content/3/1/19
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and higher TBARs. It is therefore possible that, the
observed effect may be a consequence of this association.
Others studies reported that HAART medications may
increase oxidative stress levels above and beyond levels
caused by the virus itself. In HIV infection, reactive oxygen
species may enhance viral replication by activating
nuclear transcription factors, which ultimately lead to
viral gene expression. Further, in HIV-infected adults,
zidovudin was shown to promote oxidative damage to
DNA, a process that was reversible with vitamin C and
vitamin E supplementation [12]. Several pre-HAART stud-
ies found that both asymptomatic HIV-infected individu-
als and AIDS patients had higher levels of oxidative stress,
as indicated by increased plasma metabolites of lipid per-
oxidation and/or reduced antioxidant levels, compared
with healthy controls [13,14]. HAART may induce (i) an
increase in oxidant generation, (ii) a decrease in anti-oxi-
dant protection, or (iii) a failure to repair oxidative dam-
age. Oxidative stress-mediated cell damage occurs, in part,
via reactive oxygen species (ROS). ROS include molecules
like hydrogen peroxide; ions like the hypochlorite ion;
radicals like the hydroxyl radical; and the super oxide
anion which is both ion and radical. Radicals (also called
"free radicals") are a cluster of atoms that contain an
unpaired electron in their outermost orbit of electrons.
This is an extremely unstable configuration, and radicals
quickly react with other molecules or radicals to achieve
the stable configuration. Once formed, ROS participate in
a number of reactions, yielding additional free radicals
such as hydrogen peroxide, peroxynitrite, or hypochlo-
rous acid [15]. The free radicals in HIV infection could
result also from non-enzymatic protein oxidation and the
subsequent oxidative degradation of glycated proteins.
We noticed that, increase in oxidative stress brought about
by HIV infection as well as the use of therapy was paral-
leled by significant decreases in glutathione (GSH) level
(sulfhydryls group) and albumin, as well as Vitamin C
with Therapy I. Abnormally high levels of free radicals as
well as the simultaneous decline of antioxidant defence
mechanisms can lead to damage of cellular organelles and
enzymes as well as increased lipid peroxidation. Under
normal conditions, numerous cellular antioxidant sys-
tems exist to defend against oxidant stress and maintain
the redox balance of the cell. ROS are cleared from the cell
by enzymatic systems including superoxide dismutases
(SODs), catalase, and glutathione peroxidase, or the
nonenzymatic system including alpha-tocopherol (vita-
min E), ascorbic acid (vitamin C), glutathione, and uric
acid. Glutathione peroxidase plays an important role as
defense mechanism in mammals, against oxidative dam-
age by catalyzing the reduction of a variety of hydroperox-
ides, using glutathione as the reducing substrate. In
addition to its role as a substrate in GSH redox cycle, glu-
tathione, also act as a direct endogenous scavenger of
hydroxyl radicals, involved in detoxification and metabo-
lism of a number of substances in the liver [16]. HAART
may reduce GSH synthesis, enhanced GSH utilization, or
limited intracellular reduction of its oxidized form
(GSSG) [16]. As a consequence of GSH deficiency, a
number of related functions may be impaired such as a
decrease in reducing capacity, protein biosynthesis,
immune function, accumulations of lipid peroxidation
products and detoxification capacity. A reduced detoxifi-
cation capacity in the liver may lead to the accumulation
of hepatotoxic metabolites leading to liver damage
[16,17]. Antiviral therapy could also have a role in oxida-
tive stress resulting from the destruction of tissues and
liver cells and the activation of neutrophils and macro-
phages. The major damage to cells results from the ROS-
induced alteration of macromolecules such as polyunsat-
urated fatty acids in membrane lipids, essential proteins
and DNA [18]. Indirect oxidative damage of proteins is
also possible, through their interaction with reactive carb-
onyl compounds formed by the auto-oxidation of carbo-
hydrates and lipids [19,20]. The differences in oxidative
stress as well as in the plasma concentrations of antioxi-
dants between pre HAART patient and HAART patient
may be explain by their nutritional status. Malnutrition
can have a severe impact on the specific antigen-antibody
components of the immune system and can also compro-
mise general bodily defence mechanisms [20] and was
common in HIV-infection prior to the introduction of
highly active antiretroviral therapy (HAART). Although
HAART result in suppression of viral replication and dra-
matic improvement in clinical, immunological [21], and
nutritional status, as shown our results, weight loss and
wasting may still be observed in some patients on ARV
treatment. We noticed that, 10 % of HAART patients were
underweight and chronic diarrhoea, opportunist infec-
tions, were the primary contributors to these nutritional
deficiencies and may induce a decrease in the level of anti-
oxidant capacity (sulfhydryls group). The increase in lipid
peroxidation found in HAART patients may also be
explaining by the lipodystrophy syndrome. Previous stud-
ies suggested that lipodystrophy syndrome in HIV-posi-
tive individuals on HAART is characterized by
subcutaneous fat wasting, visceral fat accumulation, lipid
abnormalities, and insulin resistance or glucose intoler-
ance [22]. Certain aspects of this syndrome may be asso-
ciated with oxidative stress, thereby increasing the body's
demand for certain antioxidants [23,24]
Conclusion
HIV infection increases the oxidative stress process, while
anti retroviral combination therapy compounds this effect
by increasing lipid oxidation. The decrease in antioxidants
that accompanies HIV infection suggests a potentially
important role of nutritional supplementation and goodPublish with BioMed Central    and   every 
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nutrition in general in the proper management of HIV/
AIDS.
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